<DOC>
	<DOCNO>NCT02362165</DOCNO>
	<brief_summary>Bortezomib-based triple-drug combination greatly improve response rate multiple myeloma patient . Bortezomib , doxorubicin , dexamethasone ( PAD ) commonly use clinical practice.Recent study find cyclophosphamide , bortezomib , dexamethasone ( CyBorD ) seem good PAD efficacy . However , randomize phase 3 trial compare two regimen treatment newly diagnose multiple myeloma patients.In study , investigator compare efficacy safety two regimen use once-weekly subcutaneous injection bortezomib .</brief_summary>
	<brief_title>CyBorD vs. PAD Treatment Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>Bortezomib-based triple-drug combination greatly improve response rate multiple myeloma patient . Bortezomib , doxorubicin , dexamethasone ( PAD ) commonly use clinical practice . Recent study find cyclophosphamide , bortezomib , dexamethasone ( CyBorD ) seem good PAD efficacy . However , randomize phase 3 trial compare two regimen treatment newly diagnose multiple myeloma patient . Moreover , study find subcutaneous injection bortezomib decrease incidence rate peripheral neuropathy induce bortezomib , however , center use twice-weekly administration bortezomib . According experience , once-weekly subcutaneous injection bortezomib decrease incidence rate peripheral neuropathy without compromise efficacy . Thus , phase 3 trial , investigator compare efficacy safety two regimen use once-weekly subcutaneous injection bortezomib .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnosis multiple myeloma Eastern Cooperative Oncology Group ( ECOG ) status 03 , Estimated survival time &gt; 3 month Acceptable liver function ( bilirubin＜2.5×ULN , Alanine transaminase ( ALT ) Aspartate Aminotransferase ( AST ) ＜2.5×ULN ) No history malignancies No previous treatment include chemotherapy , radiotherapy , target therapy stem cell transplantation No serious disease conflict treatment present trial No concurrent treatment conflict treatment present trial Voluntary participation sign informed consent . The patient condition : clinically significant ventricular tachycardia ( VT ) , atrial fibrillation ( AF ) , heart block , myocardial infarction ( MI ) , congestive heart failure ( CHF ) , symptomatic coronary artery heart disease require medication ; The patient participate clinical trial within 30 day enrollment participate clinical study The patient neuropathy The patient mentally ill / unable obtain informed consent The patient drug addiction , alcohol abuse affect longterm evaluation test result The patient pregnancy , lactation woman childbearing age want take contraceptive measure subject The patient history allergy test drug The patient suitable participate investigator judge researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>bortezomib</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>peripheral neuropathy</keyword>
</DOC>